Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 357 results for "cadila health"

Cadila launches cheaper copy of top-selling drug in India
Business Today India

Cadila launches cut-price version of world's top-selling drug

Mumbai. — Indian drug-maker Cadila Healthcare Ltd said yesterday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its US price. The drug's branded version ... Zimbabwe Herald, 1 week ago
Cadila launches cheaper copy of top-selling drug in India Business Today India, 1 week ago
[x]  
Livemint.com

Cadila Healthcare Ltd clarifies on recall of benzonatate capsules

Posted On: 2014-12-17 20:30:20 The Exchange had sought clarification from Cadila Healthcare Ltd with respect to news appearing in DNA on December 17, 2014 titled "Cadila's US Arm recalls 63,648 bottles of benzonatate capsules."Cadila Healthcare ...
 Equity Bulls3 days ago Cadila recalls Benzonatate capsules from US markets  The Financial Chronicle3 days ago Nod by international regulators key for Cadila: Dandekar  Moneycontrol.com1 week ago Cadila Healthcare slips on buzz of recalling bottles of hypertension drug in US  Capital Market1 week ago
[x]  
Firstpost.com

Govt caps prices of 52 more 'essential' drugs

Email this Print Related to : Lupin Ltd,Cadila Healthcare Ltd Lupin Ltd BSE 12 Dec 14 | 02:16 PM 1449.65 13 (0.9%) NSE 12 Dec 14 | 02:04 PM 1459.35 22.3 (1.55%) The government has capped the prices of 52 more drugs, including ...
 Business Standard India1 week ago India extends price caps to 52 more essential drugs  Yahoo! Finance1 week ago UPDATE 2-India extends price caps to 52 more essential drugs  Reuters1 week ago India caps prices of 52 more "essential" drugs - pricing authority  Yahoo! Finance1 week ago
[x]  

Cadila Healthcare unveils cheaper copy of top drug

Expecting sales between Rs 1 billion to Rs 2 billion from its biosimilar: Cadila Drugmaker Cadila Healthcare Ltd said on Tuesday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world’s top-selling drug, at ...
 Asian Age1 week ago
Financial Express

Cadila recalls drug in US

Mumbai, Oct. 17: Cadila Healthcare has voluntarily recalled 5,400 bottles of anti-hypertension drug Atenolol tablets in the US for failing to meet specifications. A notification by the US Food and Drug Administration (USFDA) said the recall was ...
 Calcutta Telegraph2 months ago Cadila Healthcare recalls anti-hypertension drug in US  Hindu Business Line2 months ago Cadila Healthcare recalls blood pressure drug in the US  Business Standard India2 months ago Empty capsules lead to Aurobindo drug recall  DNA India3 weeks ago
[x]  
Business Standard India

Pharma index hits new high

Cadila Healthcare, Glenmark Pharm, Dr Reddy's Lab, Sun Pharma and Aurobindo up 1-6%, hits new high today. SI Reporter | Mumbai November 7, 2014 Last Updated at 13:04 IST Shares of pharmaceutical companies are on a roll with the National Stock ...
 Business Standard India1 month ago IT, pharma stocks lead decline  Business Standard India2 weeks ago

Cadila recalls chest pain and hypertension tablets in US

Ahmedabad-based Cadila Healthcare's US division has voluntarily initiated recall of 5,400 bottles of atenolol tablets in the United States for failing to meet certain specifications. The drug is used to treat chest pain and hypertension. It is ...
 DNA India2 months ago CADILA HEALTHCARE : recalls chest pain, hypertension tablets in US  4 Traders2 months ago

Buy Cadila Health, Canara Bk, Capital First: Dharmesh Kant

Dharmesh Kant of India Nivesh Securities is of the view that one can buy Capital First for a target price of Rs 330 and Canara Bank for a target price of Rs 390.
 Money Control2 months ago

Bull's Eye: Buy Arvind, Cadila Health; short Sesa Sterlite

AK Prabhakar, Independent Advisor advises buying Arvind for a target price of Rs 340 and Sobha Developer for a target price of Rs 488.
 Money Control2 months ago

Sensex, Nifty hit six-week closing low

Sensex lost 229.09 points or 0.82% to settle at 27,602.01. The market breadth indicating the overall health of the market was weak. Shares of oil exploration and production companies declined after overnight sharp decline in global crude oil prices.
 Business Standard India1 week ago Indian stock market and companies daily report (December 18, 2014, Thursday)  Stock Markets Review3 days ago Indian stock market daily morning report (November 10, 2014, Monday)  Stock Markets Review1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less